All Pathways
DermatologyEmergency

DRESS Syndrome Management

DRESS Syndrome Management: Suspected DRESS Syndrome → STOP Culprit Drug Immediately → Assess Clinical Features → Calculate RegiSCAR Score → RegiSCAR Int...

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Suspected DRESS Syndrome

    Rash + fever + systemic involvement 2-8 weeks after new drug

    1. Action

      STOP Culprit Drug Immediately

      Identify and discontinue causative medication

      • Top 5 culprits: Allopurinol, Vancomycin, Lamotrigine, Carbamazepine, TMP-SMX
      • Other: Phenytoin, minocycline, dapsone, abacavir
      • Onset typically 2-8 weeks after starting drug
      • Can occur with drugs taken for years (rare)
      1. Action

        Assess Clinical Features

        Key manifestations of DRESS

        • Skin: Morbilliform eruption (90%), facial edema (50%)
        • Fever: >38°C (90%)
        • Lymphadenopathy: Present in 50-75%
        • Hematologic: Eosinophilia >700/µL (90%), atypical lymphocytes
        • Organ involvement: Liver (80%), kidney (40%), lung (30%), heart (rare but serious)
        1. Decision

          Calculate RegiSCAR Score

          Validated diagnostic scoring system

          • Fever ≥38.5°C: 0 (no/unknown), -1 (yes)
          • Enlarged lymph nodes (≥2 sites, >1cm): 0 (no), 1 (yes)
          • Eosinophilia: 0 (<700), 1 (700-1500), 2 (>1500 or if WBC<4000, eos>10%)
          • Atypical lymphocytes: 0 (no), 1 (yes)
          • Skin involvement: >50% BSA = 1
          • Skin suggestive of DRESS (2/3: edema, infiltration, purpura, scaling): 1
          • Biopsy suggesting DRESS: 0 (no), -1 (no/other diagnosis), 1 (yes)
          • Organ involvement: 1 (one organ), 2 (≥2 organs)
          • Resolution ≥15 days: -1 (no), 0 (yes)
          • Evaluation for 3+ causes negative: 0 (no), 1 (yes)
          1. Action

            RegiSCAR Interpretation

            Score determines likelihood of DRESS

            • <2: No case (unlikely DRESS)
            • 2-3: Possible case
            • 4-5: Probable case
            • ≥6: Definite case
            • Note: More sensitive than Japanese SCAR criteria
            1. Action

              Initial Workup

              Laboratory and imaging evaluation

              • CBC with differential (eosinophils, atypical lymphocytes)
              • LFTs (ALT/AST, bilirubin, ALP)
              • Renal function (Cr, BUN)
              • Cardiac: Troponin, BNP if symptoms, ECG
              • Viral: HHV-6, HHV-7, EBV, CMV PCR/serology
              • Consider: Chest X-ray, urinalysis, TSH
              • Skin biopsy if diagnosis uncertain
              1. Action

                Mild DRESS

                No significant organ dysfunction

                • Skin-predominant symptoms
                • Mild LFT elevation (<3x ULN)
                • No cardiac, renal, or pulmonary involvement
                • May manage outpatient with close follow-up
                1. Action

                  Mild: Supportive Care

                  No systemic immunosuppression needed

                  • Topical high-potency corticosteroids
                  • Emollients for skin care
                  • Antihistamines for pruritus
                  • Monitor LFTs weekly initially
                  1. Action

                    Ongoing Monitoring

                    DRESS requires prolonged follow-up

                    • LFTs, renal function: Weekly during acute phase
                    • CBC with differential: Monitor eosinophils
                    • HHV-6 reactivation may cause symptom flare
                    • TSH at 2-3 months (autoimmune thyroiditis common)
                    • Monitor for autoimmune diseases (up to 3-5 years)
                    • Document culprit drug for future avoidance
                    1. Outcome

                      Resolution

                      Typical recovery 2-8 weeks after drug withdrawal

                      • Skin resolves first, organ dysfunction later
                      • Steroid taper slowly over 6-12 weeks
                      • Drug allergy documentation essential
                      • Cross-reactivity testing before related drugs
                      • Risk of late autoimmune sequelae
                    2. Warning

                      Complications / Death

                      Mortality ~10%, late sequelae common

                      • Hepatic failure, multi-organ failure
                      • Sepsis (especially during immunosuppression)
                      • Late autoimmune: Thyroiditis (most common), T1DM, lupus
                      • Recurrence with re-exposure to culprit/cross-reactive drugs
              2. Action

                Moderate DRESS

                Single organ involvement

                • Hepatitis (ALT >3x ULN)
                • Renal impairment
                • Significant eosinophilia (>5000/µL)
                • Admit for monitoring
                1. Action

                  Moderate: Systemic Corticosteroids

                  First-line immunomodulatory therapy

                  • Prednisone 0.5-1 mg/kg/day
                  • Or methylprednisolone IV if unable to take PO
                  • Continue until organ function normalizes
                  • Slow taper over 6-8 weeks minimum
                  • Rapid taper may cause flare
                  • Monitor for steroid side effects
              3. Warning

                Severe DRESS

                Multi-organ or life-threatening

                • Hepatic failure (ALT >10x ULN, jaundice)
                • Renal failure
                • Cardiac involvement (myocarditis)
                • Pulmonary involvement
                • Hemophagocytic lymphohistiocytosis (HLH)
                • ICU admission often required
                1. Action

                  Severe: Escalated Therapy

                  For steroid-resistant or multi-organ failure

                  • High-dose pulse steroids: Methylprednisolone 1g/day x 3 days
                  • Cyclosporine 3-5 mg/kg/day if steroid-refractory
                  • IVIG 2 g/kg over 2-5 days (controversial)
                  • Consider mycophenolate, rituximab for refractory cases
                  • Contraindicated during active sepsis: Rituximab

Guideline Source

Management of Adult Patients with DRESS: Delphi International Consensus

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • Diagnosis can be challenging due to variable presentation
  • Viral reactivation testing may not be available emergently
  • Long-term monitoring required for autoimmune sequelae
  • Steroid tapering requires individualization
  • Cross-reactivity testing should guide future drug avoidance

Applicable Regions

USEU
Version 1Next review: 2027-01-11

Frequently Asked Questions

What is the DRESS Syndrome Management?

The DRESS Syndrome Management is a emergency clinical algorithm for Dermatology. It provides a structured decision tree to guide clinical decision-making, based on Management of Adult Patients with DRESS: Delphi International Consensus.

What guideline is the DRESS Syndrome Management based on?

This algorithm is based on Management of Adult Patients with DRESS: Delphi International Consensus (DOI: 10.1001/jamadermatol.2023.4014).

What are the limitations of the DRESS Syndrome Management?

Known limitations include: Diagnosis can be challenging due to variable presentation; Viral reactivation testing may not be available emergently; Long-term monitoring required for autoimmune sequelae; Steroid tapering requires individualization; Cross-reactivity testing should guide future drug avoidance. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the DRESS Syndrome Management appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free